Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Biofrontera Inc. reported revenue of $42M, up 11.7% year over year. Operating margin was -27.2% and net margin -25.3%, on a free-cash-flow margin of -32.0% with capital expenditure at 0.0% of revenue. Every figure is computed directly from BFRI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $42M | -27.2% | -25.3% |
| FY2024 | $37M | -46.1% | -47.6% |
| FY2023 | $34M | -66.6% | -59.1% |
| FY2022 | $29M | -64.8% | -2.2% |
| FY2021 | $24M | -104.6% | -156.5% |
How does BFRI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.